News and Comments

Exeixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015

 More...

Incyte is A Great Biotech Firm

  Saturday, November 07, 2015

To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say do not get panicky. Nothing is wrong with Incyte, no bad news was announced with any of the firm’s 12 ongoing clinical trials or with its approved drug Jakafi, which demonstrated progressive growth since it was launched.  So, a clever correct move now would be taking advantage and accumulate INCY.  More...

Dyax Acquisition and Biocryst Future

  Tuesday, November 03, 2015

 More...

Another Durable Botulinum Toxin with Many Advantages Over Botox

  Thursday, October 29, 2015

Another Durable, Botulinum Toxin with Many Advantages More...

Cytokinetics Heart Failure Drug Worked

  Tuesday, October 27, 2015

POSITIVE TOP-LINE RESULTS FROM A PHASE 2 TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH CHRONIC HEART FAILURE More...

URGENT BREAKING NEWS

  Thursday, October 22, 2015

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with underlying advanced liver disease.  More...

The Stream of Exelixis Good News is Real

  Thursday, October 22, 2015


 More...

Sarepta Versus Biomarin: Trying to make an Educated Guess

  Monday, October 19, 2015

About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to decide upon reviewing Biomarin’s (BMRN) Duchenne muscular dystrophy (DMD) drug Drisapersen a few weeks earlier than reviewing Sarepta (SRPT) DMD drug Eteplirsen.  More...

Incyte And Merck Agree to Expand Their agreement Regarding their Immunotherapy Combination Drugs

  Tuesday, October 13, 2015

 More...

Yesterday Market Performance Brings Back Hope in Normalcy. Compugen Announced Some Encouraging News.

  Thursday, October 08, 2015

Stories From Yesterday Market More...


Recent Postings


Archive


Tags

AERIE PHARMACEUTICALS Intercept (ICPT) Vertex (VRTX) Spike Therapeutics (ONCE) Sequenom (SQNM) CompuGen (CGEN) Jazz Pharmaceuticals (JAZZ) ISIS (ISIS) Zerenex Theravance (THRX) AstraZeneca (AZN) Prosensa (RNA) Exelixis (EXEL) SYNTA (SNTA) Global Cell Therapeutics (GBT) Aimmune Therapeutics (AIMT) Xoma (XOMA) Rapamune RenenxBio (RGNX) Tysabri Adaptimmune (ADAP) Biocryst (BCRX) Bellicum (BLCM) Alnylam (ALNY) OSI (OSIP) Illumina (ILMN) Gilead (GILD) ARCA (ABIO) Auspex (ASPX) Dendreon (DNDN) TOKAI (TKAOI) ZALTRAP™ Anadys (ANDS) Alder Biopharmaceuticals (ALDR) Onyx (ONXX) HALOZYME (HALO) SUNESIS PHARMACEUTICALS (SNSS) Array Pharmaceuticals (ARRY) NANTKWEST (NK) Pluristem (PSTI) REGULUS (RGLS) KERYX (KERX) Herceptin SERES THERAPEUTICS (MCRB) GUARDIAN HEALTH Merck (MRK) Elan (ELN) Idenix (IDIX) Ariad (ARIA) Valeant Pharmaceuticals International (VRX) Ziofpharm (ZIOP) Bristol-Myers Squibb (BMY) VANDA (VNDA) C4 Therapeutics Micromet (MITI) Inovio (INO) Velcade (bortezomib) Agenus (AGEN) Regeneron (REGN) Prolor Biotech (PBTH) ABBVIE (ABBV) INNOVIVA (INVA) Roche (ROCHE) MODERNA ADVENTRIX (ANX) Mirati Therapeutics (MRTX) Anacor (ANAC) Incyte (INCY) Sanofi (SNA) PTC Therapeutics (PTCT) Intrexon (XON) NEKTAR (NKTR)) Ionis (IONS) Agenus (AGEN AGOS (ARGS) Galena (GALE) Telaprevir Biogen Idec (BIIB) Sarepta (SRPT) Sangamo (SGMO) ACADIA (ACAD) Revlimid (lenolidamide) Sanofi (SNY) ARGOS (ARGS) Seattle Genetics (SGEN) GlaxoSmithKline (GSK) Theravance Bio Pharma (TBPH) Human Longevity (HLI) Vitae Pharmaceuticals (VTAE) Dynavax (DVAX) JUNO (JUNO) Ridaforolimus CRISPR Therapeutics (CRSP) Editas (EDIT) NOVOCURE (NVCR) Endometrial Cancer Trastuzumab-DM1 Sanofi-Aventis (SAN) IDERA (IDRA) galapagos (GLPG) Genentech KITE (KITE) Abbott Laboratories (ABT) Roche (RHHBY) Human Genome Sciences (HGSI) ImmunoGen (IMGN) Advaxis (ADXS) Amgen (AMGN) Multiple Myeloma Intermune (ITMN) Benlysta (belimumab) BIOMARIN (BMRN) Cytokinetics (CYTK)